Research programme: alpha-7 nicotinic acetylcholine receptor agonists - Roche

Drug Profile

Research programme: alpha-7 nicotinic acetylcholine receptor agonists - Roche

Alternative Names: Nicotinic alpha-7 receptor agonists - Memory Pharmaceuticals/Roche; α7 nAChR agonists - Memory Pharmaceuticals/Roche

Latest Information Update: 05 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Memory Pharmaceuticals
  • Developer Roche
  • Class
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists; Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease; Schizophrenia

Most Recent Events

  • 05 Sep 2007 Preclinical development is ongoing
  • 06 Mar 2006 This programme is still in active development
  • 09 Feb 2004 Preclinical trials in Schizophrenia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top